Clinical Trial Update: Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating autologous non-hematopoietic peripheral blood stem cells for safety and efficacy in COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• Autologous non-hematopoietic peripheral blood stem cells

Snippet

Sponsor: Abu Dhabi Stem Cells Center | Conditions: Coronavirus Disease 2019 (COVID-19) | Phase 1, Phase 2 | Status: COMPLETED